Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infectio
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09- Influenza due to certain identified influenza viruses
- Registration Number
- CTRI/2020/12/029575
- Lead Sponsor
- Central Council for Research in Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. On the day of admission patients who have been tested positive with SARS-CoV2 virus through RT PCR
2. Patients with mild symptoms
or
Patients with moderate symptoms with respiratory rate < 30 per minute and oxygen saturation > 90%
1.COVID-19 patients with symptoms classified as severe or critical.
2.Suspected COVID-19, not tested positive for COVID-19 by RT-PCR
3.Persons with severe primary respiratory disease or pneumonia
4.Pregnant and lactating women
5.Persons with severe illness such as Cancer, Heart Disease, Stroke, Mental disorder, etc., and who are considered to be excluded from the study as evaluated by the Investigators
6.COVID-19 positive cases simultaneously participating as subjects in the interventional arm of other COVID-19 clinical trials
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - Duration of subsidence of fever, respiratory and other COVID-19 symptomsTimepoint: Day 0 to Day 14
- Secondary Outcome Measures
Name Time Method â?¢Time taken to get COVID-19 RT-PCR test negative <br/ ><br>â?¢Incidence of patients progressing to next stage with regards to severity <br/ ><br>â?¢Duration of Hospital and ICU stay <br/ ><br>â?¢The use of supplementary Oxygen (Days for which oxygen was required) <br/ ><br>â?¢Any clinical reported adverse events reported (and whether the drug had to be discontinued due to the adverse effect) <br/ ><br>â?¢Quality of life scores on WHO <br/ ><br>Timepoint: Day 14